openPR Logo
Press release

Keloid Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Novartis Pharmaceuticals, Aviva Pharma

07-19-2023 05:37 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Keloid Market

Keloid Market

(Las Vegas, Nevada, United States) DelveInsight's "Keloid Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Keloid, historical and forecasted epidemiology as well as the Keloid market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Download Sample Report to know more
https://www.delveinsight.com/sample-request/keloid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Keloid Overview
Keloid, also known as keloid disorder and keloidal scar, is the formation of a type of scar which, depending on its maturity, is composed mainly of either type III (early) or type I (late) collagen. It is a result of an overgrowth of granulation tissue (collagen type 3) at the site of a healed skin injury which is then slowly replaced by collagen type 1. Keloids are firm, rubbery lesions or shiny, fibrous nodules, and can vary from pink to the color of the person's skin or red to dark brown in color. A keloid scar is benign and not contagious, but sometimes accompanied by severe itchiness, pain, and changes in texture. In severe cases, it can affect the movement of the skin.
Signs and symptoms of the disease include Thick, irregular scarring, typically on the earlobes, shoulders, cheeks, or middle chest. Shiny, hairless, lumpy, raised skin.
Varied size, depending on the size of the original injury and when the keloid stops growing.Varied texture, from soft to firm and rubbery.

Click here to learn more about the Keloid Market Landscape @https://www.delveinsight.com/report-store/keloid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlight from Keloid Market Report
True incidence and prevalence of keloid in the United States is not known. Indeed, there has never been a population study to assess the epidemiology of this disorder. In his 2001 publication, Marneros[19] stated that the "reported incidence of keloids in the general population ranges from a high of 16% among the adults in the Democratic Republic of the Congo to a low of 0.09% in England," quoting from Bloom's 1956 publication on the heredity of keloids.[20] Clinical observations show that the disorder is more common among sub-Saharan Africans, African Americans and Asians, with unreliable and very wide estimated prevalence rates ranging from 4.5 to 16%

Keloid Treatment Market
Treatments (both preventive and therapeutic) available are pressure therapy, silicone gel sheeting, intra-lesional triamcinolone acetonide, cryosurgery (freezing), radiation, laser therapy (pulsed dye laser), interferon (IFN), fluorouracil (5-FU) and surgical excision as well as a multitude of extracts and topical agents. Appropriate treatment of a keloid scar is age-dependent: radiotherapy, anti-metabolites, and corticosteroids would not be recommended to be used in children, in order to avoid harmful side effects, like growth abnormalities.
In adults, corticosteroids combined with 5-FU and PDL in triple therapy, enhance results and diminish side effects

Learn more about the treatment market for Keloid @ https://www.delveinsight.com/report-store/keloid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Keloid Epidemiology Segmented by
Keloid Prevalent cases
Keloid Incident Cases
Keloid treatment cases
Keloid Diagnosed cases
Keloid Dug Profile and Companies Covered
Novartis Pharmaceuticals
Aviva Biopharmaceuticals
MiRagen Therapeutics Inc
Rxi Pharmaceuticals
Oculus Innovation Inc
And many others.

Learn more about the Key Companies and Emerging Therapies in the Hemophilia Market @ https://www.delveinsight.com/report-store/keloid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Keloid Introduction
Executive Summary of Keloid
Disease Background and Overview
Keloid Epidemiology and patient population
Keloid Emerging Therapies
Keloid Market Outlook
Keloid Market Access and Reimbursement of Therapies
Keloid Market Drivers
Keloid Market Barriers
Appendix
Keloid Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Keloid Market Outlook report @ https://www.delveinsight.com/report-store/keloid-market utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports
Keloid Epidemiology Forecast
https://www.delveinsight.com/report-store/keloid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Keloid Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Novartis Pharmaceuticals, Aviva Pharma here

News-ID: 3138025 • Views:

More Releases from DelveInsight Business Research LLP

RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EM …
DelveInsight's "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Tria …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Amyotrophic
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA …
DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment

All 5 Releases


More Releases for Keloid

Hypertrophic and Keloid Scar Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Hypertrophic and Keloid Scar Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. Hypertrophic and Keloid Scar Treatment Market Size and Scope The hypertrophic and keloid scar treatment market focuses on solutions designed to reduce, manage,
Keloid Treatment Market is tend to be around 3.50%
The Keloid Treatment Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends. This comprehensive report provides key insights into the Keloid Treatment market, exploring critical market segmentation and definitions. It highlights the essential components driving growth, offering a clear picture of
Keloid Treatment Market: Intralesional corticosteroid injections to remain most …
According to the latest market report published by Future Market Insights titled‘Keloid Treatment Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027),’the global keloid treatment market is estimated to be worth US$ 3,145.8 Mn by 2017 end, and is expected to expand at a CAGR of 3.4% over the forecast period of 2017–2027 to reach a market valuation of US$ 4,414.6 Mn by the end of 2027. To know key findings
Keloid Treatment Market Professional Survey Report 2024
Global Keloid Treatment Market: Overview The British Skin Foundation describes a keloid scar as an overgrown scar that spreads beyond the original area of the damaged skin. It is a growth of extra scar tissue in the place where the skin has healed post-injury. Keloids can appear anywhere on the body and affect an estimated 10-15% of all wounds. Request Brochure- https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12152 There are several established treatment options available for keloid scars, including laser
Keloid Treatment Market Professional Survey Report 2024
Global Keloid Treatment Market: Overview The British Skin Foundation describes a keloid scar as an overgrown scar that spreads beyond the original area of the damaged skin. It is a growth of extra scar tissue in the place where the skin has healed post-injury. Keloids can appear anywhere on the body and affect an estimated 10-15% of all wounds. There are several established treatment options available for keloid scars, including laser treatment,
Keloid Treatment Market, Industry Analysis, Research Report 2024
Global Keloid Treatment Market: Overview The British Skin Foundation describes a keloid scar as an overgrown scar that spreads beyond the original area of the damaged skin. It is a growth of extra scar tissue in the place where the skin has healed post-injury. Keloids can appear anywhere on the body and affect an estimated 10-15% of all wounds. There are several established treatment options available for keloid scars, including laser